Vacinas COVID-19 e suas implicações imunológicas: uma revisão de literatura
COVID-19 vaccines and immunological implications: A literature review
Larissa Albuquerque; Raffaela Neves Mont'Alverne Napoleão; Liana Andrade Oliveira; Paula Danielle Santa Maria Albuquerque de Andrade
Resumo
A COVID-19 e seus mecanismos imunológicos são, atualmente, temas de grande relevância mundial. Suas manifestações clínicas e as perigosas complicações decorrentes da tempestade de citocinas motivaram a criação de vacinas contra o SARS-CoV-2 em um ritmo acelerado, gerando desconfianças e diferentes níveis de eficácia e segurança. Este estudo trata-se de um artigo de revisão que abordou pesquisas publicadas no período de 2020 e 2021, utilizando as bibliotecas eletrônicas SciELO (Scientific Electronic Library Online), PubMed, LILACS (Literatura Latino-Americana e do Caribe em Ciências da Saúde) e MEDLINE com o rastreamento específico por meio dos seguintes descritores: vacinas COVID-19, SARS-CoV-2, imunologia do COVID-19. Questões como o mecanismo imunológico, eficácia e efeitos adversos das vacinas disponíveis no mercado mundial atual foram amplamente discutidas.
Palavras-chave
Abstract
COVID-19 and immunological mechanisms currently are topics of great worldwide relevance. Clinical manifestations and the dangerous complications resulting from a cytokine storm motivated the creation of vaccines against SARS-CoV-2 at an accelerated pace, generating suspicions and different levels of efficacy and safety. This is a review article addressing research published in 2020 and 2021. The electronic libraries SciELO (Scientific Electronic Library Online), PubMed, LILACS (Latin American and Caribbean Literature in Health Sciences), and MEDLINE were used for specific screening with the following descriptors: COVID19 vaccines, SARS-CoV-2, immunology of COVID-19. Issues such as the immunological mechanism, efficacy, and adverse effects of vaccines currently available on the world market are widely discussed.
Keywords
Referências
1. Litman GW, Rast JP, Fugmann SD. The origins of vertebrate adaptive immunity. Nat Rev Immunol. 2010;10:543-53.
2. Silverstein AM. Cellular versus humoral immunology: a century-long dispute. Nat Imumunol. 2003;4:425-8.
3. Silverstein AM. Paul Erlich’s receptor immunology: the magnificent obsession. New York: Academic Press; 2001.
4. Minotti C, Tirelli F, Barbieri E, Giaquinto C, Doná D. How is immunosuppressive status affecting children and adults in SARS CoV-2 infection? A systematic review. J Infect. 2020;1(81):61-6.
5. Lhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270-3.
6. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A, Antonakos N, et al. Complex immune dysregulation in covid-19 patients with severe respiratory failure. Cell Host Microbe. 2020;27(6):992-1000.e3.
7. Sharma O, Sultan AA, Ding H, Triggle CR. A review of the progress and challenges of developing a vaccine for COVID-19. Front Immunol. 2020;11:585354.
8. Kfouri RA, Petraglia TCMB, Lima EJF, Sato HK, Giamberardino HI, Andrade SD, et al.; Departamento Científico de Imunizações da Sociedade Brasileira de Pediatria. Guia Prático de Atualização: Vacinas COVID-19 [Internet]. Disponível em: https://www.sbp.com.br/fileadmin/user_upload/22908f-GPA-Vacinas_COVID19_-_ Atualizacao.pdf .
9. Kim JH, Marks F, Clemens JD. Looking beyond COVID-19 vaccine phase 3 trials. Nat Med. 2021;27:205-11.
10. Rawat K, Kumari P, Saha L. COVID-19 vaccine: a recent update in pipeline vaccines, their design and development strategies. Eur J Pharmacol. 2021;892:173751.
11. Park KS, Sun X, Aikins ME, Moon JJ. Non-viral COVID-19 vaccine delivery systems. Adv Drug Deliv Rev. 2021;169:137-51.
12. Li YD, Chi WY, Su JH, Ferrall L, Hung CF, Wu TC. Coronavirus vaccine development: from SARS and MERS to COVID-19. J Biomed Sci. 2020;27(1):104.
13. Izda V, Jeffries MA, Sawalha AH. COVID-19: a review of therapeutic strategies and vaccine candidates. Clin Immunol. 2021;222:108634.
14. Sax PE. Covid-19 vaccines – Frequently asked questions. N Engl J Med. 2021. Disponível em: https://www.nejm.org/covidvaccine/ faq?cid=DM108101_&bid=351542135 .
15. Kremsner P, Mann P, Bosch J, Fendel R, Gabor JJ, Kreidenweiss A, et al. Phase 1 assessment of the safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 in human volunteers. Medrxiv 2020. Disponível em: https://doi.org /10.1101/2020.11.09.20228551.
16. Rauch S, Roth N, Schwendt K, Fotin-Mleczek M, Mueller SO, Petsch B. mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents. Vaccines. 2021;6(57).
17. Kfouri RA, Petraglia TCMB, Lima EJF, Sato HK, Giamberardino HI, Andrade SD, et al.; Departamento Científico de Imunizações da Sociedade Brasileira de Pediatria. Guia Prático de Atualização: Dúvidas sobre vacinas COVID-19 - Perguntas e Respostas. [Internet]. Disponível em: https://www.sbp.com.br/fileadmin/user_upload/22909c-GPA-Duvidas_sobre_Vacinas_COVID19. pdf.
18. Oldenburg J, Klamroth R, Langer F, Albisetti M, von Auer C, et al. Diagnosis and management of vaccine-related thrombosis following AstraZeneca COVID-19 vaccination: guidance statement from the GTH. Hamostaseologie. 2021. doi: 10.1055/a-1469-7481.
19. Jones I, Roy P. Sputnik V COVID-19 vaccine candidate appears safe and effective. Lancet. 2021;397(10275):642-3.
20. Baraniuk C. COVID-19: what do we know about sputnik v and other Russian vaccines? BMJ. 2021;372:n743.
21. Livingston EH, Malani PN, Creech CB. The Johnson & Johnson Vaccine for COVID-19. JAMA. 2021;325(15):1575.
22. Prada L, Ferreira J. COVID-19, diabetes e vacinas. Revista Portuguesa de Diabetes. 2020;15(4):131-8.
23. Souto XM. Vacinas contra a COVID-19: estado da arte. Revista Educ Ciência e Tecnol Almenara (MG). 2020;2(2):12-35.
24. Tregoning JS, Brown ES, Cheeseman HM, Flight KE, Higham SL, et al. Vaccines for COVID-19. Clin Exp Immunol. 2020;202(2):162‑92.
25. Mahase E. COVID-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant. BMJ. 2021;372:n296.
26. Kostoff RN, Briggs MB, Porter AL, Spandidos DA, Tsatsakis A. COVID-19 vaccine safety. Int J Mol Med. 2020;46(5):1599-602.
27. Pacheco TJA, Souza DG, Borges KNN, Pires JO, Fabbrin ASS, Santos PHM, et al. One year after the WHO alert for COVID-19: what is next? Braz J Dev. 2021;7(3):29968-78.
28. Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586(7830):589-93.
29. Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020;383(20):1920-31.
30. Zhang Y, Zeng G, Pan H, Li C, Kan B, Hu Y, et al. Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: report of the randomized, double-blind, and placebo-controlled phase 2 clinical trial. MedRxiv. 2020. doi: 10.1101/2020.07.31.20161216.
Submetido em:
20/05/2021
Aceito em:
19/08/2021
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email